← All trials
NCT05369377
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2022
- Primary completion
- Jun 1, 2025
- Completion date
- Dec 30, 2025
- First posted
- May 11, 2022
- Last posted
- May 11, 2022
- Enrollment
- 150
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Peking UniversityLead sponsor
- Capital Medical UniversityCollaborator
- Peking UniversityCollaborator
- Peking UniversityCollaborator
- Peking UniversityOverall official - principal investigator
- Peking UniversityReponsible party - principal investigator
- Shandong UniversityCollaborator
- Government of ChinaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.